Oruka SVP sells shares, exercises stock options
Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported a mix of stock option exercises and share sales in Oruka common stock.
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported a mix of stock option exercises and share sales in Oruka common stock. On May 18, 2026, he exercised 7,833 employee stock options at exercise prices of $34.39 and $12.50 per share, converting derivative awards into common shares. The same day, he sold 10,290 common shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan, at weighted average prices spanning approximately $57.72 to $61.76 per share. This pattern reflects routine option exercise paired with partial share sales for liquidity under a pre-planned program.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
8 txns
Insider
Agarwal Arjun
Role
Senior Vice President, Finance
Sold
10,290 shs ($608K)
Approx. gross sale proceeds
$608K
Approx. exercise cost
$226K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 2,000 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) | 5,833 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,000 | $12.50 | $25K |
| Exercise | Common Stock | 5,833 | $34.39 | $201K |
| Sale | Common Stock | 4,190 | $58.3449 | $244K |
| Sale | Common Stock | 4,600 | $59.1869 | $272K |
| Sale | Common Stock | 800 | $60.3364 | $48K |
| Sale | Common Stock | 700 | $61.1606 | $43K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 182,167 contracts (Direct);
Common Stock — 16,406 shares (Direct)
Footnotes (7)
- F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.72 to $58.71, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.76 to $59.75, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.78 to $60.72, inclusive.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.82 to $61.76, inclusive.
- F6. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
- F7. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Key Figures
Shares sold: 10,290 shares
Options exercised: 7,833 shares
Higher exercise price: $34.39/share
+4 more
7 metrics
Shares sold
10,290 shares
Total common shares sold on May 18, 2026
Options exercised
7,833 shares
Shares acquired via employee stock option exercises
Higher exercise price
$34.39/share
Exercise price for one employee stock option grant
Lower exercise price
$12.50/share
Exercise price for another employee stock option grant
Sale price range low
$57.72/share
Lowest price in disclosed sale ranges
Sale price range high
$61.76/share
Highest price in disclosed sale ranges
Net share direction
-10,290 shares
Net buy/sell shares from transaction summary
Key Terms
Rule 10b5-1 trading plan, weighted average price, Employee Stock Option (right to buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Option (right to buy) financial
"Employee Stock Option (right to buy) ... underlying security title: Common Stock"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transactions did ORKA executive Arjun Agarwal report?
Arjun Agarwal reported both stock option exercises and share sales. He exercised 7,833 employee stock options and sold 10,290 Oruka Therapeutics common shares in open-market trades, all dated May 18, 2026, according to the Form 4 filing.
What stock options did the Oruka Therapeutics insider exercise?
The filing shows exercises of 7,833 employee stock options. These options had exercise prices of $34.39 and $12.50 per share and were converted into Oruka Therapeutics common stock, reducing the derivative positions and increasing non-derivative share holdings.
Does the Form 4 show remaining Oruka Therapeutics stock options?
Yes. The derivative section lists employee stock options with remaining balances after the exercises, including grants with expiration dates in 2035 and 2036, indicating the insider continues to hold significant option-based exposure to Oruka Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
